Hexarelin: The Old-School GH Peptide with a Heart-Focused Twist
A clear, evidence-first look at hexarelin: a potent 1990s growth hormone peptide with intriguing but animal-only cardiac claims and real desensitisation issues.
By Research Rats Editorial TeamReviewed by Research Rats Editorial Team
Evidence profile
Assessed 2026-06-13A potent ghrelin-receptor agonist with solid short-term human GH data and an intriguing GH-independent cardiac mechanism (CD36) — but the cardiac claims are entirely animal, the one 16-week human study showed the GH effect desensitises with IGF-1 and body composition barely moving, and it was never approved. WADA-prohibited.
GHS-R1a agonism plus a separate, well-characterised cardiac CD36 mechanism.
Rich rat/ex-vivo cardiac literature (GH-independent cardioprotection).
Human GH dose-response and one 16-week study in which IGF-1 and body composition barely moved.
Acute GH yes, but the chronic human study showed little durable effect; cardiac benefit unproven in humans.
Acute and 16-week human tolerability known; long-term and net cardiac effect unknown.
Never approved; never reached Phase 3.
Confident on acute GH and desensitisation; cardiac translation unproven.
Unapproved; WADA-prohibited; grey-market.
Bars show the state of evidence, not desirability. A strong rating on any axis does not mean a compound is safe, effective, or recommended. Human evidence is often limited. Not medical advice.
What to know before reading further
Free for everyone — safety, evidence and regulatory context are never members-only.
Evidence context
A potent ghrelin-receptor agonist with solid short-term human GH data and an intriguing animal cardiac mechanism — but the cardiac claims are animal-only, and a 16-week human study showed the GH effect desensitises with little change in IGF-1 or body composition.
Safety snapshot
Acute and 16-week human tolerability are known; long-term and net cardiac effect are unknown. It raises cortisol/prolactin and can reduce insulin sensitivity, and an animal coronary-vasoconstriction signal is unresolved in humans.
Regulatory & legality
Never approved; WADA-prohibited; grey-market.
Where claims can exceed the evidence
Acute GH release is real but not durable; cardioprotection is unproven in humans.
This article does not provide dosing, protocol, administration, sourcing, stack, or self-experimentation guidance, or personalised medical advice. It is educational and non-prescriptive — the evidence profile describes the state of research, not an individual decision.
Overview
Hexarelin (also called examorelin) is one of the better-studied synthetic growth hormone-releasing peptides (GHRPs). It emerged from 1990s endocrine research and has a genuine, if limited, human pharmacology record alongside a surprisingly rich animal literature on heart protection. In humans, it reliably triggers a strong pulse of growth hormone (GH) [1]. In rats, it does something more unusual: it protects the heart through a mechanism that has nothing to do with GH at all [7][8].
That split personality is the key to understanding hexarelin. The human GH data are real but early-stage and short-term. The headline cardiac claims, by contrast, rest almost entirely on rodent and isolated-heart studies. It was never approved by any major regulator, never reached Phase 3, and today exists only as a research chemical [6]. This article walks through what is actually known, where the evidence is solid, and where it is thin.
Disclaimer. For educational and research purposes only. Not medical advice. We do not sell peptides or compounds.
This detailed research report is available to members
Research Rats is an 18+ educational research platform. Member-only content provides structured evidence interpretation only. It is not medical advice, dosing guidance, protocol guidance, sourcing guidance, cycle design, stack design or treatment advice.
Free safety information remains available where possible.
To continue, create an account or log in and agree to the Terms of Website Use, Privacy Notice, Cookie and Site Technologies Policy, and Medical, Health and Research Disclaimer.
Member access does not provide medical advice, dosing advice, sourcing advice, protocol guidance or treatment recommendations. How Research Rats works
[ Related research ]
CJC-1295 With DAC: The GHRH Analog That Made It to Human Trials
An evidence-first look at CJC-1295 with DAC: real human PK/PD data, how albumin-binding extends its half-life to days, and why development was halted.
CJC-1295 Without DAC (Mod GRF 1-29): What the Evidence Actually Shows
A plain-English, evidence-first look at CJC-1295 without DAC: what it is, why its half-life is short, what the research does and does not show, and the real risks.
GHRP-2 (Pralmorelin): What the Evidence Actually Shows
GHRP-2 reliably triggers a growth hormone pulse and ramps up hunger, but the physique and longevity claims rest on weak, mostly acute data.
GHRP-6: The Original GH-Releasing Peptide That Started It All
GHRP-6 is the first GH-releasing hexapeptide and ghrelin-receptor agonist — strong acute GH evidence, robust hunger effect, but largely superseded by cleaner analogues.